Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice

Diabetes, Obesity and Metabolism

Volumn 16, Issue 4, 2014, Pages 376-380

  Tatarkiewicz, K ^a   Polizzi, C ^a   Villescaz, C ^a   D'Souza, L J ^a   Wang, Y ^a   Janssen, S ^a   Parkes, D G ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Combination; Dapagliflozin; Diabetes; Exenatide; Glucagon like peptide 1; Mouse

Indexed keywords

CREATININE; DAPAGLIFLOZIN; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; EXPERIMENTAL DIABETES MELLITUS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE URINE LEVEL; GLUCOSURIA; HEMOGLOBIN BLOOD LEVEL; MALE; MONOTHERAPY; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OSMOTIC MINIPUMP; SINGLE DRUG DOSE; URINE VOLUME; WEIGHT REDUCTION; ANIMAL; BLOOD; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; METABOLISM; NONOBESE DIABETIC MOUSE;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED NOD; PEPTIDES; VENOMS;

EID: 84895167192     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12237     Document Type: Article

References (11)

1. Parkes DG, Mace KF, Trautmann ME. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov 2013; 8: 219-244.
2. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
3. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013; 36(Suppl. 1): S67-74.
5. Whaley JM, Tirmenstein M, Reilly TP et al. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2012; 5: 135-148.
6. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224.
7. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
8. Elvert R, Wille A, Wandschneider J, Werner U, Glombik H, Herling AW. Energy loss via urine and faeces-a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight. Diabetes Obes Metab 2013; 15: 324-334.
9. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006; 7: 367-374.
10. Kasichayanula S, Liu X, Benito MP et al. The influence of kidney function on dapagliflozin exposure, metabolism, and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2013; 76: 432-444.
11. Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010; 9: 32.